Anifrolumab for Adolescent Discoid Lupus Erythematosus

Katharina S Shaw; Ahmad Rajeh; Todd Le; Philip J Kahn; Vikash S Oza; Lisa M Arkin; Ruth Ann Vleugels

doi:10.1001/jamanetworkopen.2023.38200

Anifrolumab for Adolescent Discoid Lupus Erythematosus

JAMA Netw Open. 2023 Oct 2;6(10):e2338200. doi: 10.1001/jamanetworkopen.2023.38200.

Authors

Katharina S Shaw^{1

2}, Ahmad Rajeh³, Todd Le^{4

5}, Philip J Kahn⁶, Vikash S Oza^{6

7}, Lisa M Arkin^{4

5}, Ruth Ann Vleugels^{3

8}

Affiliations

¹ Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
³ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁴ Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison.
⁵ Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison.
⁶ Division of Pediatric Rheumatology, Department of Pediatrics, Hassenfeld Children's Hospital at NYU Langone Health, New York University Grossman School of Medicine, New York.
⁷ The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York.
⁸ Dermatology Program, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts.

No abstract available

Plain language summary

This case series describes the outcomes among adolescent patients with systemic lupus erythematosus and refractory discoid lupus erythematosus treated with anifrolumab.

Publication types

Letter

MeSH terms

Adolescent
Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Lupus Erythematosus, Discoid* / drug therapy

Substances

anifrolumab
Antibodies, Monoclonal, Humanized